RCUS
NYSEArcus Biosciences Inc.
Price$23.79+0.35 (+1.49%)
01:30 PM07:45 PM
News · 26 weeks710%
2025-12-142026-06-07
Mix3190d
- SEC Filings11(35%)
- Insider11(35%)
- Other6(19%)
- Earnings2(6%)
- Analyst1(3%)
Latest news
25 items- INSIDERDirector Lambert Nicole was granted 5,700 shares, increasing direct ownership by 15% to 43,000 units (SEC Form 4)4 - Arcus Biosciences, Inc. (0001724521) (Issuer)
- INSIDERDirector Kaneko Yasunori was granted 5,700 shares, increasing direct ownership by 28% to 25,700 units (SEC Form 4)4 - Arcus Biosciences, Inc. (0001724521) (Issuer)
- INSIDERDirector Machado Patrick was granted 5,700 shares, increasing direct ownership by 15% to 44,300 units (SEC Form 4)4 - Arcus Biosciences, Inc. (0001724521) (Issuer)
- INSIDERGeneral Counsel Tang Carolyn C. exercised 34,090 shares at a strike of $2.57, increasing direct ownership by 23% to 184,607 units (SEC Form 4)4 - Arcus Biosciences, Inc. (0001724521) (Issuer)
- INSIDERDirector Lacey David L. was granted 5,700 shares, increasing direct ownership by 8% to 76,652 units (SEC Form 4)4 - Arcus Biosciences, Inc. (0001724521) (Issuer)
- INSIDERDirector Ribas Antoni was granted 5,700 shares, increasing direct ownership by 15% to 44,300 units (SEC Form 4)4 - Arcus Biosciences, Inc. (0001724521) (Issuer)
- INSIDERDirector Perlman Andrew J was granted 5,700 shares, increasing direct ownership by 13% to 48,325 units (SEC Form 4)4 - Arcus Biosciences, Inc. (0001724521) (Issuer)
- INSIDERDirector Falberg Kathryn E was granted 5,700 shares, increasing direct ownership by 15% to 44,300 units (SEC Form 4)4 - Arcus Biosciences, Inc. (0001724521) (Issuer)
- SECArcus Biosciences Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - Arcus Biosciences, Inc. (0001724521) (Filer)
- PRArcus Biosciences Announces New Employment Inducement GrantsArcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer and inflammatory and autoimmune diseases, today announced that the Compensation Committee of the Company's Board of Directors granted one new employee options to purchase a total of 2,850 shares of the Company's common stock at an exercise price per share of $23.32, which was the closing price on June 8, 2026, and restricted stock units to acquire a total of 1,450 shares of the Company's common stock. The equity awards were granted pursuant to the Company's 2020 Inducement Plan, which was approved by the Compa
- INSIDERChief Accounting Officer Azoy Alexander sold $66,024 worth of shares (2,562 units at $25.77) as part of a pre-agreed trading plan, decreasing direct ownership by 6% to 39,581 units (SEC Form 4)4 - Arcus Biosciences, Inc. (0001724521) (Issuer)
- PRArcus Biosciences to Participate in the Goldman Sachs 47th Annual Global Healthcare ConferenceArcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer and inflammatory and autoimmune diseases, announced that its management team will participate in a fireside chat at the upcoming Goldman Sachs Global Healthcare Conference in Miami Beach, FL. The fireside chat will take place on Tuesday, June 9th, 2026, at 10:40am ET. A live webcast of the presentation will be available by visiting the "Investors & Media" section of the Arcus Biosciences website at www.arcusbio.com. A replay will be available following the live event. About Arcus Biosciences Arcus Bioscience
- ANALYSTTruist resumed coverage on Arcus Biosciences with a new price targetTruist resumed coverage of Arcus Biosciences with a rating of Buy and set a new price target of $35.00
- INSIDERChief Financial Officer Goeltz Ii Robert C. sold $198,966 worth of shares (7,763 units at $25.63) as part of a pre-agreed trading plan, decreasing direct ownership by 8% to 84,161 units (SEC Form 4)4 - Arcus Biosciences, Inc. (0001724521) (Issuer)
- INSIDERDirector Ribas Antoni gifted 5,050 shares, decreasing direct ownership by 12% to 38,600 units (SEC Form 4)4 - Arcus Biosciences, Inc. (0001724521) (Issuer)
- SECSEC Form 144 filed by Arcus Biosciences Inc.144 - Arcus Biosciences, Inc. (0001724521) (Subject)
- SECSEC Form 144 filed by Arcus Biosciences Inc.144 - Arcus Biosciences, Inc. (0001724521) (Subject)
- SECSEC Form 10-Q filed by Arcus Biosciences Inc.10-Q - Arcus Biosciences, Inc. (0001724521) (Filer)
- SECArcus Biosciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Arcus Biosciences, Inc. (0001724521) (Filer)
- PRArcus Biosciences Reports First-Quarter 2026 Financial Results and Provides a Pipeline UpdateArcus outlines development strategy to establish casdatifan as a backbone therapy across each line of treatment for clear cell renal cell carcinoma (ccRCC), including the potential to become the first HIF-2a inhibitor-based tyrosine kinase inhibitor (TKI)-free regimen in the first-line (1L) setting Phase 3 PEAK-1 study is enrolling in immunotherapy (IO)-experienced patients with ccRCC, with enrollment completion and the initiation of a 1L Phase 3 study both expected by year-end 2026 Arcus selected its first inflammation program clinical candidate AB102, an MRGPRX2 antagonist, which is expected to enter the clinic in the third quarter of 2026; its preclinical profile will be present
- PRArcus Biosciences Announces New Employment Inducement GrantsArcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer and inflammatory and autoimmune diseases, today announced that the Compensation Committee of the Company's Board of Directors granted one new employee options to purchase a total of 4,200 shares of the Company's common stock at an exercise price per share of $25.13, which was the closing price on April 23, 2026, and restricted stock units to acquire a total of 2,100 shares of the Company's common stock. The equity awards were granted pursuant to the Company's 2020 Inducement Plan, which was approved by the Com
- SECSEC Form 144 filed by Arcus Biosciences Inc.144 - Arcus Biosciences, Inc. (0001724521) (Subject)
- SECSEC Form DEFA14A filed by Arcus Biosciences Inc.DEFA14A - Arcus Biosciences, Inc. (0001724521) (Filer)
- SECSEC Form DEF 14A filed by Arcus Biosciences Inc.DEF 14A - Arcus Biosciences, Inc. (0001724521) (Filer)
- PRArcus Biosciences to Host Conference Call to Discuss First-Quarter 2026 Financial Results and Pipeline UpdatesArcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer and inflammatory and autoimmune diseases, announced that its management team will host a conference call and webcast on Tuesday, May 5, 2026 at 1:30 PM PT / 4:30 PM ET to discuss details of the Company's financial results and pipeline updates for the quarter ended March 31st, 2026. Investors interested in listening to the conference call may do so by dialing +1 (585) 542-9983 (local) or +1 (833) 461-5787 (toll-free), using Meeting ID: 304747896. Participants may also register for the call online using the follow
RCUS FAQ
7 questionsWhat does Arcus Biosciences Inc. do?
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for monotherapy. The company is also developing Domvanalimab, an anti-TIGIT monoclonal antibody, which is in Phase 2 development for the treatment of first-line metastatic non-small cell lung cancer in combination with Zimberelimab; and AB680...Where does RCUS stock trade?
Arcus Biosciences Inc. (RCUS) is listed on NYSE.What sector and industry is RCUS in?
Arcus Biosciences Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Arcus Biosciences Inc. go public?
Arcus Biosciences Inc. (RCUS) completed its IPO in 2018.What are analysts saying about RCUS?
Arcus Biosciences Inc. has had 8 recent analyst actions on file. The most recent action was from Truist: Buy with a $3500.00 price target on 2026-05-18. Recent price targets range from $2000.00 to $3500.00.What companies are similar to RCUS?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), AZN (AstraZeneca PLC), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare RCUS side-by-side with any of them on Quantisnow.How can I track RCUS on Quantisnow?
Quantisnow aggregates Arcus Biosciences Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow RCUS to receive live email and push alerts on every new disclosure.